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A B S T R A C T
Objective: To establish a hospital-based surveillance network with national coverage for antimicrobial
resistance (AMR) and antibiotic consumption in Viet Nam.
Methods: A 16-hospital network (Viet Nam Resistance: VINARES) was established and consisted of
national and provincial-level hospitals across the country. Antimicrobial susceptibility testing results
from routine clinical diagnostic specimens and antibiotic consumption data in Defined Daily Dose per
1000 bed days (DDD/1000 patient-days) were prospectively collected and analysed between October
2012 and September 2013.
Results: Data from a total of 24 732 de-duplicated clinical isolates were reported. The most common
bacteria were: Escherichia coli (4437 isolates, 18%), Klebsiella spp. (3290 isolates, 13%) and Acinetobacter
spp. (2895 isolates, 12%). The hospital average antibiotic consumption was 918 DDD/1000 patient-days.
Third-generation cephalosporins were the most frequently used antibiotic class (223 DDD/1000 patient-
days, 24%), followed by fluoroquinolones (151 DDD/1000 patient-days, 16%) and second-generation
cephalosporins (112 DDD/1000 patient-days, 12%). Proportions of antibiotic resistance were high: 1098/
1580 (69%) Staphylococcus aureus isolates were methicillin-resistant (MRSA); 115/344 isolates (33%) and
90/358 (25%) Streptococcus pneumoniae had reduced susceptibility to penicillin and ceftriaxone,
respectively. A total of 180/2977 (6%) E. coli and 242/1526 (16%) Klebsiella pneumoniae were resistant to
imipenem, respectively; 602/1826 (33%) Pseudomonas aeruginosa were resistant to ceftazidime and 578/
1765 (33%) to imipenem. Of Acinetobacter spp. 1495/2138 (70%) were resistant to carbapenems and 2/333
(1%) to colistin.
Conclusions: These data are valuable in providing a baseline for AMR among common bacterial pathogens
in Vietnamese hospitals and to assess the impact of interventions.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Viet Duc Hospital, Saint-Paul Hospital, Uong Bi Hospital, Viet Tiep Hospital, Hue Central General Hospital, Da Nang General Hospital, Binh Dinh General Hospital, Dak Lak
General Hospital, Khanh Hoa Provincial Hospital, Cho Ray Hospital, Children’s Hospital 1, Hospital for Tropical Disease, and Can Tho Central Hospital.
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1. Introduction
Antimicrobial resistance (AMR) among common bacterial
pathogens is a recognised global health threat, leading to a
significant increase in healthcare costs, treatment failures and
deaths [1]. The issue is more pressing in low-income and middle-
income countries (LMICs) like Viet Nam, where the burden of
resistant infections is disproportionate, while data and evidence
on the exact burden and epidemiology are scarce [2].
Overuse and inappropriate use of antibiotics is an important
driver for the emergence and spread of AMR. The World Health
Organization (WHO) introduced a six-point policy package on
World Health Day 2011, including surveillance of antimicrobial
resistance and use and rational antimicrobial use [3]. This served as
the framework for the Global Action Plan and most National Action
Plans composed by member states. The WHO also published a
comprehensive set of recommendations to track antimicrobial use
and resistance in bacteria, and to ensure a better use of antibiotics
and reduce antimicrobial use in animal husbandry [4]. In Viet Nam,
there is substantial overuse of antimicrobial drugs, both in the
animal health sector and in the human health sector in hospitals
and the community [5,6]. An observational study of antibiotic sales
in northern Viet Nam showed high proportions of transactions at
pharmacies that included antibiotics: 24% in urban sites and 30% in
rural sites; the large majority were without prescription [7].
Since1988,anumberof nationalandinternationaleffortshavebeen
made to implement AMR surveillance in Viet Nam, on different scales.
Table 1 describes the objectives, scale and results of each project. The
Viet Nam Resistance network (VINARES) was launched in 2012 as a
collaboration between the Ministry of Health, Vietnamese Infectious
Diseases Society, Oxford University Clinical Research Unit-Viet Nam
(OUCRU),andLinköpingUniversity,Sweden, togetherwith16hospitals
acrossthecountry[8].Thisstudydescribestheantimicrobialsensitivity
testing (AST) results from clinical specimen isolates from the
microbiology laboratories, and antimicrobial consumption data from
the VINARES hospitals’ pharmacies between October 2012 and
September 2013. These results provide an update on earlier results
published in the situation analysis [6] and recommendations for data
collection improvement to use as evidence for design and implemen-
tation of targeted interventions to tackle antibacterial overuse and
resistance in Viet Nam.
2. Materials and methods
2.1. Data collection
The VINARES network was previously described [8]. Sixteen
hospitals were included: seven in the northern, three in the central
and six in the southern region of Viet Nam. These include national-
level (n = 7) and provincial-level (n = 9) hospitals; two tropical
Table 1
Result of antimicrobial resistant surveillance programs and studies in Viet Nam from 1988–2011.
Project Year Scale Vietnamese
sites
Description Result of program
NPSAR (former
ASTS) [25] [26]
1988–
2006
Viet
Nam
9 (in 1988)
31 (1993)
NPSAR – implemented by MoH – was a national surveillance
program for AMR. Bacteria causing infectious diseases in
inpatients and outpatients were isolated and tested for
antibiotic susceptibility.
E. coli producing ESBL: 7.7% (42/548)
K. pneumoniae producing ESBL: 23.7% (115/485)
ANSORP [27] 1996 Asia 1 Children’s Hospital 2, HCMC, participated in a project of
surveillance for pneumococcal resistance among clinical S.
pneumoniae isolates that were collected from 14 centres in 11
countries in Asia and the Middle East between 2000 and 2001.
Proportion of penicillin non-susceptibility S.
pneumoniae (71.4%) in Viet Nam, highest among
participant countries.
Amoxicillin/clavulanic acid (AMC) resistance rate
was 22.2%.
ANSORP [28] 2004–
2006
Asia 1 A prospective, multinational surveillance study with
molecular typing analysis that was performed to understand
the changing epidemiology of S. aureus infections in Asian
countries.
University of Medicine and Pharmacy in HCMC, Viet
Nam reported that hospital-acquired and
community-acquired S. aureus were 74.1% and 30.1%,
respectively. Second highest rates of MRSA among
participants, lower than Sri Lanka.
Multi-center
evaluation
study on S.
aureus
bacteraemia
[19]
2008–
2009
Global 3 This study assessed the variation in management and
adherence to treatment guidelines of S. aureus bacteraemia
treated consecutively over 1 year in eight centres in the United
Kingdom, three in Viet Nam and one in Nepal.
80 patients (19%) from Viet Nam had methicillin-
resistant S. aureus bacteraemia.
GARP [6] 2009 Global 15 GARP-Viet Nam and the University of Oxford collaborated with
the Vietnamese MoH to set up new antibiotic resistance
surveillance program. A cross-sectional study was performed
to collect antibiotic resistance and antibiotic use data from 15
participating hospitals 2009.
E. coli resistant to cefuroxime (30–80%), to SXT from
60–80%.
E. coli and K. pneumoniae producing ESBL were 15–
57% and 7–73%, respectively.
40% of Pseudomonas aeruginosa and 60% of
Acinetobacter spp. were resistant to ceftazidime.
SOAR [22] 2009–
2011
Global 11 A study on AMR surveillance of respiratory pathogens. Isolates
of S. pneumoniae and H. influenzae were obtained from clinical
materials taken from adults and paediatric patients with
community-acquired respiratory infections.
47.8% and 93.1% of S. pneumoniae were non-
susceptible to penicillin and resistant to
azithromycin.
40.5% of H. influenzae produced β-lactamase.
Resistances to AMC for S. pneumoniae and H.
influenzae were low (3.1% and 2.6%, respectively).
SMART [29] 2009–
2011
Global 4 A study on antimicrobial susceptibility rates in aerobic Gram-
negative bacteria causing intra-abdominal infections in Viet
Nam (2 sites in HCMC and 2 sites in Hanoi).
ESBL positive in E. coli and K. pneumoniae were 48.1%
and 39.5%, respectively. 7.7% of 13 P. aeruginosa
isolates were resistant to ceftazidime but none to
ciprofloxacin.
Abbreviations: AMR, antimicrobial resistance; NPSAR, National Program for Surveillance in Antimicrobial Resistance; ASTS, antimicrobial sensitivity testing study; MoH,
Ministry of Health; ESBL, extended spectrum beta-lactamase; AMC, amoxicillin/clavulanic acid; ANSORP, Asian Network for Surveillance of Resistant Pathogens; HCMC, Ho
Chi Minh City; MRSA, methicillin-resistant Staphylococcus aureus (S. aureus); GARP, Global Antibiotic Resistance Partnership; SXT, trimethoprim/sulfamethoxazole; SOAR,
Survey of Antibiotic Resistance; SMART, Study for Monitoring Antimicrobial Resistance Trends; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; S. pneumoniae,
Streptococcus pneumoniae; H. influenza, Haemophilus influenzae; P. aeruginosa, Pseudomonas aeruginosa.
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diseases, two paediatric and one surgical hospital(s) (Fig. 1).
Antibiotic consumption was reported monthly by the pharmacy
department. Each department was provided with a laptop and an
Excel file to enter the details of antibiotic consumption in the
intensive care unit (ICU) and whole hospital. In a few cases,
patients had to buy outside medicine that was not available in the
pharmacy department (e.g. colistin). This situation was ignored in
this study, but it did not affect the results as it was very rare.
Fig. 1. Location, specialty and type of the 16 participating hospitals in the project.
T.V.D. Vu et al. / Journal of Global Antimicrobial Resistance 18 (2019) 269–278 271
A baseline laboratory assessment was conducted at the 16
participating hospitals. Laboratories were provided with American
Type Culture Collection (ATCC) reference strains for internal
quality control and were enrolled into the monthly UK NEQAS
identification and AST external quality assessment programme.
Each laboratory performed identification and susceptibility tests
on an isolate that was sent monthly by UK NEQAS, and uploaded
the result on their website. UK NEQUAS assessed the test results
and returned the report to OUCRU. Each laboratory was provided
with a laptop, surveillance database software (WHONET) [9], and
up-to-date Vietnamese-translated Clinical Laboratory Standards
Institute (CLSI) guidelines (M100-S22) [10]. Staff from all
participating sites were trained during several workshops on
microbiology methods and the use of WHONET. A helpdesk was set
up to address any issues throughout the project. Reported data,
including AST results from bacterial isolates from clinical speci-
mens sent in for routine diagnostics and hospital-wide antibiotic
consumption in the 16 participating hospitals, were sent monthly
from October 2012 to September 2013. The AST results were
entered manually into WHONET or exported from automated AST
as VITEK2 (bioMérieux, Marcy l’Étoile, France) or LABCONN
(Labsoft, Viet Nam) using BacLink (provided with WHONET).
There were four hospitals that used automated systems, 11 used
manual and one used both. A configuration file was developed for
each laboratory to convert data. Both AST and antimicrobial usage
data were submitted regularly or on request by email.
All duplicate isolates for the same patient (identical specimen type
and bacterium) in the AST dataset were excluded following WHO
recommendations [11]. Results obtained by disk diffusion (DD) and
minimum inhibitory concentration (MIC) methods were combined. If
both were performed, the MIC result was used. Reported resistance
rates are the proportion of bacteria with the AST showing resistance
(result = R). Intermediate susceptible isolates (result = I) were not
considered as resistant. Results were accepted, analysed and reported
as is and, generally, no confirmatory testing of unexpected results or
rare phenotypes in reference or central laboratories was performed
according to current practice in most LMICs.
2.2. Data analysis
The number and proportion of nine indicator bacteria —
Acinetobacter spp., Pseudomonas aeruginosa (P. aeruginosa), Hae-
mophilus influenzae (H. influenzae), Escherichia coli (E. coli),
Klebsiella spp., Staphylococcus aureus (S. aureus), Enterobacter
spp., Enterococcus faecium (E. faecium), and Streptococcus pneumo-
niae (S. pneumoniae) – were described overall by patient age group,
sex and specimen type.
An S. aureus isolate was counted as multi-resistant (MRSA) if it
tested resistant to oxacillin or cefoxitin in screening. Similarly, S.
pneumoniae isolates were counted as reduced susceptibility to
penicillin if resistance to oxacillin by disk diffusion was reported
(also if unconfirmed by MIC testing). Resistance rates were reported
for all specimens combined and for a subgroup of invasive isolates
from blood and cerebrospinal fluid (CSF). The proportion assessed
by disk diffusion or MIC was reported if applicable. A sample was
considered resistant to an antibiotic class if it was resistant to at
least one antibiotic agent in that class, as per CLSI guidelines.
Antibiotic consumption was summarised in number of Defined
Daily Dose per 1000 bed days (DDD/1000 patient-days). The DDD is
the assumed average maintenance dose per day for a drug used for
its main indication in adults, which can be obtained from the WHO
Antimicrobial DDD Quick Reference List [12]. The DDD/1000
patient-days was calculated by antibiotic class and did not depend
on bed size of hospital.
For each bacteria-antibiotic pair, the resistant proportion was
calculated as the ratio between the number of resistant isolates
and number of tested isolates for that drug. All hospitals were
anonymised and coded from H1 to H16. R software (version 3.1.11)
was used for the analysis [13].
3. Results
3.1. Distribution of bacteria and antibiotics
The AST results were reported for 26 808 isolates from the
VINARES network between October 2012 and September 2013.
After de-duplication and removal of fungi, 24 732 bacterial isolates
were included in the analysis.
The most commonly isolated organisms were: E. coli (4437
isolates, 18%); Klebsiella spp. (3290 isolates, 13%) – including 2206
K. pneumoniae isolates (9%); Acinetobacter spp. (2895 isolates, 12%)
– including 1668 Acinetobacter baumannii (A. baumannii) isolates
(7%); P. aeruginosa (2326 isolates, 9%); S. aureus (2039 isolates, 8%);
Enterobacter spp. (1067 isolates, 4%); S. pneumoniae (813 isolates,
3%); H. influenzae (404 isolates, 2%); and E. faecium (98 isolates, 1%).
Gram-negative bacteria accounted for 69% (17 065 isolates) and
Gram-positive for 31% (7667 isolates). Sputum was the most
frequently reported specimen (3625 isolates, 15%) followed by
blood (3222 isolates, 13%). Of the total isolates, 11% were recovered
from blood and CSF.
The distribution of isolates by gender and age of patient and
type of specimen for the nine indicator bacteria is summarised in
Supplementary Table S1. Among 17 369 common bacteria, a higher
proportion was isolated from male (66%) than from female patients
(34%), reflecting the usual hospital population in Viet Nam. E. coli,
K. pneumoniae, P. aeruginosa and Acinetobacter spp. (including A.
baumannii) were mainly reported from adults aged >20 years,
while S. aureus and S. pneumoniae were more commonly reported
from children aged 10 years.
The distribution of bacteria was separately stratified by
hospitals and region (Fig. 2). Acinetobacter spp. were mostly found
in two major general hospitals (H2 and H4). H. influenzae was
mainly isolated from children, with >50% from one paediatric
hospital (H11). The proportion of E. coli was similar across the three
regions and, overall, the pathogen distribution also appeared
similar across regions.
Antibioticconsumptionwasseparatelysummarisedbyhospitaland
region. One hospital (H2) did not provide consumption data. The
average antibiotic consumption was 918 DDD/1000 patient-days per
hospital. Hospitals in the central and southern region had similar
antibiotic consumption rates (1079 and 1026 DDD/1000 patient-days,
respectively), while a lower rate was reported, on average, from
hospitals in the northern region (799 DDD/1000 patient-days, after
excluding a paediatric hospital). The most commonly used antibiotics
were third-generation cephalosporins (223 DDD/1000 patient-days,
24%), fluoroquinolones (151 DDD/1000 patient-days, 16%), second-
generation cephalosporins (112 DDD/1000 patient-days, 12%), penicil-
lin combinations (111 DDD/1000 patient-days, 12%), followed by
aminoglycosides (54 DDD/1000 patient-days, 6%), penicillins with
extendedspectrum(53DDD/1000patient-days,6%), fourth-generation
cephalosporins (49 DDD/1000 patient-days, 5%), carbapenems (35
DDD/1000 patient-days, 4%) and glycopeptides (10 DDD/1000 patient-
days, 1%). Overall, third-generation cephalosporins was the largest
groupinall regions, followedbyfluoroquinolones(Fig.3).Two-thirdsof
second-generation cephalosporins  were used in the central region.
3.2. Antimicrobial susceptibilities
3.2.1. General
The proportion of isolates having ASTassessed varied by hospital;
more ASTs were performed at national hospitals than in provincial
hospitals (Supplementary Table S2). Vancomycin-susceptibility test
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for E. faecium and imipenem-susceptibility test for P. aeruginosa
were most frequently carried out across the hospitals (98% and 76%,
respectively). Four hospitals (H3, H4, H8, H12) had tested >95% of
reported isolates.
Fig. 4 illustrates the resistant proportions of each bacteria-
antibiotic combination and its relationship with the amount of
antibiotic used and the number of isolates. Second-generation
cephalosporins are not included in Fig. 4 because most hospitals
did not test for these. More than 50% of Enterobacteriaceae were
resistant to third-generation cephalosporins and fluoroquinolones.
Carbapenem-resistant proportions were highest among Acineto-
bacter spp. (around 75%), followed by P. aeruginosa (around 50%)
and lowest in Enterobacteriaceae (around 25%). S. aureus and E.
faecium were susceptible to vancomycin, but the susceptibility
results of E. faecium should be interpreted with caution because of
the low numbers. S. pneumoniae was susceptible, while nearly 50%
of H. influenzae were resistant to combinations of penicillins.
3.2.2. Antimicrobial susceptibility testing results of Gram-positive
bacteria
Table 2 shows the AST results for S. aureus, S. pneumoniae and E.
faecium. S. aureus was isolated from 2039 specimens; 258 (13%)
were from blood and CSF. Among 1580 tested, 1098 (69%) S. aureus
isolates were identified as MRSA. Similar resistance rates were
observed for isolates from blood and CSF isolates from all
specimens. D-test for induced clindamycin resistance was not
separately reported, therefore resistance may be underestimated.
The results from 813 S. pneumoniae isolates included 87 from
blood and CSF. Etests confirmed/were performed in 99% (353/358)
of ceftriaxone, 39% (86/221) of penicillin and 54% (349/641) of
vancomycin susceptibility tests. A total of 115/344 (33%) S.
pneumoniae isolates showed reduced susceptibility to penicillin;
the corresponding percentage in blood and CSF isolates
was 7/30 (23%). Streptococcus pneumoniae susceptibility to
penicillin was screened using oxacillin disks; 86 isolates were
confirmed by penicillin MIC test. Out of 194 oxacillin disk diffusion
results showing resistance, 87 (45%) were not confirmed by
penicillin susceptibility test. Regarding blood and CSF specimens,
there were six isolates confirmed by penicillin MIC test, and they
were all susceptible. Ten isolates (2%) of S. pneumoniae were
resistant to vancomycin (two of 10 resistant isolates were
confirmed by Etest). These results were not confirmed in a
reference laboratory or molecularly, and this should be interpreted
with caution.
Fig. 3. Distribution of antibiotic consumption by hospitals and regions.
Fig. 2. Distribution of bacteria by hospitals and regions. Sum of each graph is 100%.
Abbreviations: E. coli, Escherichia coli; P. aeruginosa, Pseudomonas aeruginosa; S. aureus, Staphylococcus aureus; S. pneumoniae, Streptococcus pneumoniae; H. influenzae,
Haemophilus influenzae; E. faecium, Enterococcus faecium.
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Among 98 E. faecium isolates, only one amoxicillin susceptibili-
ty test was performed. Of isolates, 78% were vancomycin
susceptible, while the proportion of normal-level gentamicin
susceptibility was <50%.
3.2.3. Antimicrobial sensitivity testing results of Gram-negative
bacteria
Enterobacteriaceae susceptibility for amikacin, cefotaxime,
ciprofloxacin, gentamicin, imipenem, tobramycin and trimetho-
prim/sulfamethoxazole (SXT) are shown in Table 3. Among the
4437 E. coli submitted, 527 (12%) were from blood and CSF and 992
(23%) from urine. More than 80% of ASTs for E. coli were carried out
by disk diffusion. Resistance was >50% for third-generation
cephalosporins and fluoroquinolones. Lower resistance levels
were seen for imipenem and amikacin. Resistance rates among
all isolates were generally higher than proportions observed in
blood and CSF isolates (P < 0.0001 for cefotaxime and ciprofloxa-
cin; P = 0.03 for SXT).
Of the 3290 available Klebsiella spp. isolates, 2206 were K.
pneumoniae. Resistance rates to third-generation cephalosporins
and carbapenems were 68% and 16%, respectively. Similar to E. coli,
proportions of resistance to cefotaxime, ciprofloxacin and SXT
were also lower among blood and CSF than all isolates (P < 0.0001
for all). Among the 1067 Enterobacter spp. isolates (82 from blood
and CSF), 21% were resistant to carbapenems.
Table 4 shows the AST results of Acinetobacter spp., P. aeruginosa
and H. influenzae. Results from 2895 Acinetobacter spp. (including
1668 A. baumannii) were submitted. Data on colistin were available
from only one hospital and two of 333 isolates were found to be
resistant. Results showed very high resistant proportions for all
Fig. 4. Resistance rate, number of isolates and number of DDD/1000 patient-days per antibiotic group.
For each bacteria-antibiotic combination, the resistant proportion was shown in bottom left figure; the number of isolates for each organism was in top left and the number of
DDD/1000 patient-days of antibiotic group was in bottom right. The resistant proportion was calculated for 15 hospitals that provided antibiotic consumption data. DDD/1000
patient-days figure illustrates the amount of antibiotic used for all bacterial treatment, not for any specific bacteria. Untested or clinically irrelevant bacteria-antibiotic
combinations were not shown.
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antibiotics, from 68% (amikacin) to 77% (ceftazidime). Resistant
proportions of Acinetobacter spp. for imipenem and amikacin in
blood and CSF were lower than in other specimens (P < 0.0001 for
both).
Of the 2326 P. aeruginosa submitted isolates, 154 were from
blood and CSF. The resistance rate to ceftazidime was 33%, which is
similar to blood and CSF specimens. Of the isolates, 33% were
resistant to imipenem, while 39% were aminoglycosides-resistant.
Blood isolates had lower aminoglycosides-resistance levels in
comparison with all isolates (P = 0.04).
H. influenzae was isolated from 404 specimens, including 10
from blood and CSF. One hundred and sixty (71%) isolates were
resistant to ampicillin. The resistance rates to amoxicillin/
clavulanic acid (AMC) and cefotaxime were 39% and 44%,
respectively.
4. Discussion
This study described the AST and antibiotic usage results
reported from the VINARES network in Viet Nam between 2012
and 2013. Overall, the data showed high proportions of AMR
among all tested bacteria across all hospitals in the network. These
results also show large variations in the resistant proportions
between hospitals. This highlights the importance of continuous
monitoring of local antibiotic use and bacterial resistance, which is
one of the core strategies in the National Action Plan on combatting
Table 2
Susceptibility result of Gram-positive bacteria isolated in the VINARES project.
Resistance/tested isolates (%) S. aureus S. pneumoniae E. faecium
All specimens
(n = 2039)
Blood and CSF
(n = 258)
All specimens
(n = 813)
Blood and CSF
(n = 87)
All specimens
(n = 98)
Blood and CSF
(n = 24)
MRSA 1098/1580 (69) 145/197 (74)
Vancomycin 22/823 (3) 2/135 (1) 10/641 (2) 1/74 (1) 21/96 (22) 3/24 (12)
Ciprofloxacin 456/1277 (36) 71/189 (38) 2/12 (17) 0/0 (NT)
Erythromycin 985/1 315 (75) 103/143 (72) 246/289 (85) 26/29 (90)
Clindamycin 639/907 (70) 74/118 (63)
Gentamicin 435/1155 (38) 55/135 (41) 26/46 (57) 8/9 (89)
Levofloxacin 333/852 (39) 40/125 (32)
SXT 261/1156 (23) 41/141 (29)
Penicillin 115/344 (33)a 7/30 (22)b
Ceftriaxone 90/358 (25) 9/52 (17)
Amoxicillin 1/1 (100) 0/0 (NT)
Abbreviations: CSF, cerebrospinal fluid; MRSA, methicillin-resistant Staphylococcus aureus; SXT, trimethoprim/sulfamethoxazole.
Untested or clinically irrelevant bacteria-antibiotic combinations were not shown.
a screened with oxacillin, 86 isolated were confirmed by MIC method and one isolate was resistant to penicillin.
b screened with oxacillin, six isolates were confirmed by MIC method and all were susceptible to penicillin.
Table 3
Susceptibility results of Escherichia coli, Klebsiella spp. and Enterobacter spp. isolated in the VINARES project.
Resistance/tested isolates (%) Escherichia coli Klebsiella spp. Enterobacter spp.
All specimens
(n = 4 437)
Blood and CSF
(n = 527)
All specimens
(n = 3 290)
Blood and CSF
(n = 413)
All specimens
(n = 1067)
Blood and CSF
(n = 82)
Amikacin 321/2936 (11) 36/394 (9) 638/2163 (29) 61/329 (19) 149/768 (19) 11/58 (19)
Cefotaxime 2342/4192 (56) 240/514 (47) 1479/2227 (66) 101/190 (53) 483/802 (60) 25/48 (52)
Ciprofloxacin 1758/3052 (58) 188/397 (47) 1 222/2305 (53) 139/332 (42) 277/741 (37) 28/63 (44)
Gentamicin 1285/2655 (48) 111/282 (39) 1042/1989 (52) 99/233 (42) 294/760 (39) 21/47 (45)
Imipenem 180/2977 (6) 15/403 (4) 393/2294 (17) 64/361 (18) 144/665 (22) 12/70 (17)
SXT 1994/2803 (71) 196/298 (66) 1242/2 007 (62) 118/236 (50) 360/709 (51) 24/51 (47)
Tobramycin 502/1309 (38) 52/247 (21) 588/1377 (43) 65/236 (28) 142/386 (37) 16/48 (33)
Abbreviations: CSF, cerebrospinal fluid; SXT, trimethoprim/sulfamethoxazole.
Table 4
Susceptibility result of Acinetobacter spp., Pseudomonas aeruginosa, Haemophilus influenzae isolated in the VINARES project.
Resistance/tested isolates (%) Acinetobacter spp. P. aeruginosa H. influenzae
All specimens
(n = 2895)
Blood and CSF
(n = 313)
All specimens
(n = 2326)
Blood and CSF
(n = 154)
All specimens
(n = 404)
Blood and CSF
(n = 10)
Amikacin 1347/1993 (68) 82/188 (44) 329/1556 (21) 13/82 (16)
Cefotaxime 118/270 (44) 5/10 (50)
Ciprofloxacin 1298/1733 (75) 74/207 (36) 496/1527 (32) 33/120 (28) 17/269 (6) 0/10 (0)
Gentamicin 1385/1837 (75) 130/214 (61) 566/1456 (39) 33/106 (31)
Imipenem 1495/2138 (70) 110/244 (45) 578/1765 (33) 36/129 (28) 33/341 (10) 0/10 (0)
SXT 1258/1799 (70) 86/192 (45) 46/60 (77) 3/5 (60)
Ceftazidime 1650/2146 (77) 124/242 (51) 602/1826 (33) 43/133 (32)
TCC 771/1128 (68) 47/141 (33)
AMC 109/276 (39) 2/5 (40)
Erythromycin 3/3 (100) 0/0 (NT)
Ampicillin 160/226 (71) 3/5 (60)
Abbreviations: CSF, cerebrospinal fluid; SXT, trimethoprim/sulfamethoxazole; TCC, ticarcillin/clavulanic acid; AMC, amoxicillin/clavulanic acid.
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drug resistance [14]. Overall, lower proportions of resistance were
found in samples taken among isolates from blood and CSF
samples, likely reflecting different proportions of hospital acquired
isolates among sample types.
Cephalosporins, fluoroquinolones and penicillin covered 70% of
antibiotic use. Hospitals were more likely to use fluoroquinolones
and less likely to use cephalosporins in 2012 (16%) than in 2008
(11%) [5]. This may be explained by the change in antibiotic
susceptibility between the two periods.
The antibiotic use DDD/1000 patient-days provides a rough
indication that 91% of patients in hospitals were on antibiotic
treatment. However, DDD/1000 patient-days is not an appropriate
measure with which to study the impact of antimicrobial
stewardship because DDD/1000 patient-days can be misrepre-
sented by use of combination therapy or of higher dosages for
certain indications or guided by therapeutic drug monitoring (not
yet practiced in Viet Nam). This biases towards higher DDD/1000
patient-days and, thus, an overestimate of antibiotic use. As
evidence of these biases in DDD/1000 patient-days measurements,
a monthly point prevalence study conducted in ICUs within
VINARES reported that the proportion of patients receiving
antibiotics at survey time was 85% (2787/3287) and that 60% of
patients were prescribed more than one antibiotic [15]. This result
was higher compared with the point-prevalence conducted in
2008 (67% (5104/7571) of patients receiving antibiotics) [5]. Two
possible explanations were that 16 of 36 participating sites of the
previous study were district-level hospitals with an expected
lower usage and that there has been an increase in use of
antibiotics in hospitals over time. The global report of antibiotic
consumption also stated an increase of 20–25 DDD/1000 patient-
days in Viet Nam in the 2010–2015 period [16].
The number of days of antimicrobial therapy (DOT) can be used
along with DDD/1000 patient-days to report antibiotic consump-
tion practices in hospital, which offers more clinical relevance [17].
The DOT reports the administration of a single agent on a given day,
regardless of the number of doses administered or dosage
concentration [18], which avoids overestimation of usage. The
DDD/1000 patient-days allows comparison of antibiotic use across
countries and hospitals, while DOT could make conclusions about
the relative use of one antibiotic compared with another [18]. The
measurement of DOT might be difficult for most hospitals [17]. The
measurement of antibiotic use by DDD/1000 patient-days and
DOT/1000 patient-days was dissimilar because the administered
dose is dissimilar from the DDD recommended by the WHO,
according to a study on 130 hospitals in USA [18].
The current study reported similar levels of resistance among
four Gram-negative bacteria — including E. coli, K. pneumoniae, P.
aeruginosa and Acinetobacter spp. — compared with the GARP
situation analysis [6]. Further studies to evaluate the changes in
antibiotic consumption and the likely effect on resistance levels at
hospitals are warranted to prioritise targets of intervention. In
addition, linking microbiology and susceptibility data with clinical
data should be aimed for in this surveillance network, to allow
assessment of the origin of the infection (community vs. hospital-
acquired) for better informing of evidence-based guidelines.
In the GARP situation analysis, an MRSA proportion of between
30–64% was reported [6]. An evaluation from 2008–2009 in three
hospitals in Viet Nam revealed an MRSA proportion of 19% in 80
patients with S. aureus bacteraemia [19]; while the current study
reported 61% of MRSA in blood and CSF specimens. Better and more
comprehensive surveillance methodology may explain the higher
proportions of MRSA bacteraemia. In VINARES, all MRSA tests were
performed by oxacillin or cefoxitin disc diffusion test, which is a
reliable proxy for detection of MRSA [20].
More than 50% of S. pneumoniae were non-susceptible to
penicillin. This was also confirmed in a recent review by WHO [21],
showing the result of penicillin non-susceptibility from 47–48% in
two countries in the South-East Asia and 17–64% in 10 countries of
Western Pacific region. However, the extent of the problem is
uncertain, partly due to variations in how reduced susceptibility is
being reported and large proportions of intermediate results. The
SOAR study reported 48% (138/289) of penicillin-non-susceptibili-
ty among S. pneumoniae [22].
Carbapenems were still mostly active against the tested
Enterobacteriaceae. Compared with 2009, there was a slight
increase of resistance to imipenem among E. coli (from 2% to 6%)
and Klebsiella pneumoniae (from 10% to 17%) [6]. Most imipenem-
susceptibility tests for Enterobacteriaceae were performed by disk
diffusion, but this may not be as reliable as broth microdilution or
other methods [23]. Klebsiella spp. showed increased resistance to
third-generation cephalosporins in comparison with a 2009
situation analysis study (from 40% to 66%). Fourth-generation
cephalosporins also had less effect on these species. For E. coli, the
current study showed similarly high resistance proportions to the
conventional agents used for treatment, such as SXT and third-
generation cephalosporins, in comparison with the 2009 situation
analysis (from 60–80%) [6]. These data showed the persistent and
increasing problem of Enterobacteriaceae resistance to third-
generation cephalosporins in the hospital setting. Even though
resistance to carbapenems in this report is still low, the levels
tended to increase from the time of the 2009 situation analysis and
are likely to continue increasing unless effective interventions are
undertaken.
P. aeruginosa was still susceptible to ceftazidime, ciprofloxacin
and imipenem, with a resistance rate around 30%. The 2009
situation analysis showed similar rates of around 40% resistance to
ceftazidime and ciprofloxacin [6]. Data from VINARES are more
likely to be representative, given the improved and quality
assessed microbiological and reporting practices. P. aeruginosa
was among the three most common aetiologies of hospital-
acquired infections in ICUs in Viet Nam in the same period [15].
This point prevalence survey showed higher resistance propor-
tions of P. aeruginosa to carbapenems (55.7%) compared with the
current surveillance results, reflecting the larger burden of
resistance in the ICU settings.
In the current study, Acinetobacter spp. also showed 70%
resistance to imipenem, while the proportion reported in the 2009
situation analysis was 40% [6]. High carbapenem resistance in
these organisms raised great concern for treatment alternatives, as
colistin is usually the last resort and an increase in colistin
resistance is likely to happen. Colistin resistance was only assessed
at one hospital in the network, and 0.6% of 333 tested isolates
showed resistance using Etest/VITEK (which are not the recom-
mended standard). Higher levels of carbapenems (85%) and colistin
(1.3 [n = 78] and 31.6% [n = 38]) resistance were reported from two
hospitals (of the three provincial and university hospitals
participating in VINARES) in southern Viet Nam in another study
from 2012–2014 [24].
VINARES reported higher AMC resistance H. influenzae com-
pared with SOAR (39% and 2.6%, respectively). This could be the
result of increasing rate over time, or due to a large overlap
between participating hospitals. Most importantly, SOAR samples
were from outpatients whereas the current ones were from
samples sent to the micro laboratories. As microbiology is
underutilised in Viet Nam (and other LMICs) this probably
represents a population with more advanced infections or a more
extensive history of pre-treatment and, thus, selection of resis-
tance pathogens. This is very illustrative of how the current AMR
surveillance overestimates resistance because of this underuse and
lack of clinical metadata and denominators.
Antimicrobial sensitivity testing was not conducted for all
reported isolates and this could have introduced bias in the
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reported resistant proportions. Three explanations can be given:
first, some ASTs are only indicated based on the results of another
(e.g. in S. aureus vancomycin was only tested for MRSA); second,
ASTs may have only been indicated when the isolates were
suspected to be the aetiological pathogen causing clinical
manifestations; and third, ASTs may have been ordered because
of failure in empirical treatment.
For future efforts to conduct antimicrobial resistance surveil-
lance and to provide more useful data for guiding local clinical
treatment and public health research, it is important for clinical
microbiology laboratories to be strengthened and better utilised.
Currently, the number of samples coming to the laboratory is low
in comparison with the number of admitted patients. It is likely
that the more severe patients, transferred patients, patients failing
primary treatment, and patients with hospital-acquired infections
are overrepresented among patients from whom samples are sent
to the laboratory. Clear clinical diagnostic and treatment guide-
lines, with consistent microbiological testing on suspicion of
infectious aetiology, could partially overcome this bias. Clinical
data should also be considered to be part of the surveillance data.
This could include clinical syndrome, date of admission, transfer
status, and antibiotic use while sampled.
5. Conclusion
This project demonstrates an initiative with a large network
of hospitals to monitor AMR in Viet Nam. Resistance proportions
to common antibiotics in 16 hospitals were remarkably high,
and most have increased since the 2009 situation analysis.
Policy development for pharmacies both in hospitals and the
community requires a structured solution to address this
problem. AMR surveillance could be improved by enhancing
capacity of clinical microbiologists through advanced training
and upgrading WHONET program with more control of data
entry and a pre-defined global configuration. Clinical data
should be included in the reports from the hospitals in future.
External quality assurance is also recommended for all testing
performed in the laboratory.
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